The deal between pharma majors Ranbaxy and Teva, for the sale of generic version of the blockbuster cholesterol drug – Lipitor left many in the industry surprised. Vikas Dandekar, Bureau Chief, PharmAsia News tells CNBC-TV18 that the contours of the deal revolved around three scenarios at best.
first published: Dec 14, 2011 09:05 pm
A collection of the most-viewed Moneycontrol videos.
Nifty At Over 3-Month Low; Will The Bulls Make A Comeback?| Opening Bell Live
Small town, Big tech: Sridhar Vembu on Zoho’s rural push, AI Bubble, SaaS consolidation & many more
Live: DAVOS 2026 Day 5 Highlights: Elon Musk, AI Innovations & India’s Investment Pitch
Budget 2026 Decoded ? Key Terms You Must Know | Inflation, Taxes & Spending
